Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch Orion, a cloud platform, running on google cloud architecture; and EpiSwitch Explorer Array Kit platform, enabling advanced analysis of 3D regulatory control points. The company was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Metrics to compare | OBD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOBDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −6.6x | −0.5x | |
PEG Ratio | −0.01 | −0.08 | 0.00 | |
Price / Book | 7.3x | 1.8x | 2.6x | |
Price / LTM Sales | 7.4x | 4.5x | 3.2x | |
Upside (Analyst Target) | - | 103.7% | 45.7% | |
Fair Value Upside | Unlock | 6.7% | 4.8% | Unlock |